A phase i trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer

Cancer Immunology, Immunotherapy

Volumn 59, Issue 12, 2010, Pages 1781-1789

  Iliopoulou, Eleni G ^a   Kountourakis, Panteleimon ^a,b   Karamouzis, Michalis V ^a,c   Doufexis, Dimitrios ^a   Ardavanis, Alexandros ^a   Baxevanis, Constantin N ^a   Rigatos, Gerasimos ^a   Papamichail, Michael ^a   Perez, Sonia A ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b Bank of Cyprus Group Oncology Centre   (Cyprus)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adoptive transfer; Allogeneic; Lung cancer; Natural killer cells

Indexed keywords

CARBOPLATIN; CD56 ANTIGEN; CISPLATIN; CORTICOSTEROID; DOCETAXEL; GEMCITABINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROCORTISONE; INTERLEUKIN 15; NAVELBINE; PACLITAXEL; PEMETREXED;

ADOPTIVE TRANSFER; ADULT; ADVANCED CANCER; AGED; ALLOTRANSPLANTATION; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTE CULTURE; MALE; NATURAL KILLER CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SAFETY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; IMMUNOTHERAPY; K562 CELL LINE; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY;

ADOPTIVE TRANSFER; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOTHERAPY; K562 CELLS; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 77957661092     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0904-3     Document Type: Article

References (40)

1. L Ruggeri A Mancusi M Capanni MF Martelli A Velardi 2005 Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer Curr Opin Immunol 17 211 217 1:CAS:528:DC%2BD2MXit1ChtLk%3D 10.1016/j.coi.2005.01.007 15766683 (Pubitemid 40343110)
2. L Ruggeri M Capanni A Mancusi K Perruccio E Burchielli MF Martelli A Velardi 2005 Natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation Int J Hematol 81 13 17 1:CAS:528:DC%2BD2MXhvFGmsbw%3D 10.1532/IJH97.04172 15717682 (Pubitemid 40165417)
3. A Moretta F Locatelli L Moretta 2008 Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias Immunol Rev 224 58 69 1:CAS:528:DC%2BD1cXhtF2qurnO 10.1111/j.1600-065X.2008.00651.x 18759920
4. S Gill JA Olson RS Negrin 2009 Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses Biol Blood Marrow Transplant 15 765 776 1:CAS:528:DC%2BD1MXos1Ojt7c%3D 10.1016/j.bbmt.2009.01.019 19539207
5. HG Ljunggren KJ Malmberg 2007 Prospects for the use of NK cells in immunotherapy of human cancer Nat Rev Immunol 7 329 339 1:CAS:528: DC%2BD2sXksFeks74%3D 10.1038/nri2073 17438573 (Pubitemid 46674487)
6. KJ Malmberg YT Bryceson M Carlsten S Andersson A Bjorklund NK Bjorkstrom BC Baumann C Fauriat E Alici MS Dilber HG Ljunggren 2008 NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy Cancer Immunol Immunother 57 1541 1552 1:CAS:528:DC%2BD1cXovFyitr4%3D 10.1007/s00262-008-0492-7 18317755
7. L Ruggeri A Mancusi E Burchielli M Capanni A Carotti T Aloisi F Aversa MF Martelli A Velardi 2008 NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation Blood Cells Mol Dis 40 84 90 1:CAS:528: DC%2BD2sXhsVWjsbvI 10.1016/j.bcmd.2007.06.029 17964828 (Pubitemid 350192306)
8. S Slavin A Ackerstein R Or MY Shapira B Gesundheit N Askenasy S Morecki 2010 Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study Cancer Immunol Immunother 59 1511 1519 1:CAS:528:DC%2BC3cXpt12lsLg%3D 10.1007/s00262-010-0878-1 20563804
9. M Carlsten KJ Malmberg HG Ljunggren 2009 Natural killer cell-mediated lysis of freshly isolated human tumor cells Int J Cancer 124 757 762 1:CAS:528:DC%2BD1MXhvVSiu7k%3D 10.1002/ijc.24082 19035446
10. D De Santis A Bishara CS Witt A Nagler C Brautbar S Slavin FT Christiansen 2005 Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants Tissue Antigens 65 519 528 10.1111/j.1399-0039. 2005.00396.x 15896199 (Pubitemid 40776300)
11. F Re C Staudacher L Zamai V Vecchio M Bregni 2006 Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors Cancer 107 640 648 1:CAS:528:DC%2BD28Xot1aksbw%3D 10.1002/cncr.22002 16804934 (Pubitemid 44107226)
12. JS Miller Y Soignier A Panoskaltsis-Mortari SA McNearney GH Yun SK Fautsch D McKenna C Le TE Defor LJ Burns PJ Orchard BR Blazar JE Wagner A Slungaard DJ Weisdorf IJ Okazaki PB McGlave 2005 Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 3051 3057 1:CAS:528:DC%2BD2MXjtlSmtb0%3D 10.1182/blood-2004-07-2974 15632206
13. M Berg A Lundqvist P McCoy Jr L Samsel Y Fan A Tawab R Childs 2009 Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells Cytotherapy 11 341 355 1:CAS:528: DC%2BD1MXlt1KmtLg%3D 10.1080/14653240902807034 19308771
14. M Berg A Lundqvist D Betters RW Childs 2009 In vitro expanded NK cells have increased natural cytotoxity receptors, TRAIL and NKG2D expression, and superior tumor cytotoxicity compared to short-term IL-2-activated NK cells Blood 114 463 (ASH Annual Meeting Abstracts)
15. PA Albertsson PH Basse M Hokland RH Goldfarb JF Nagelkerke U Nannmark PJ Kuppen 2003 NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity Trends Immunol 24 603 609 1:CAS:528: DC%2BD3sXosVyis7k%3D 10.1016/j.it.2003.09.007 14596885 (Pubitemid 37338529)
16. JM Brand B Meller K Von Hof J Luhm M Bahre H Kirchner C Frohn 2004 Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma Stem Cells Dev 13 307 314 1:CAS:528:DC%2BD2cXktlyrsbg%3D 10.1089/154732804323099235 15186726 (Pubitemid 38738372)
17. T Zhang D Herlyn 2009 Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer Cancer Immunol Immunother 58 475 492 1:CAS:528:DC%2BD1MXht1Olsbs%3D 10.1007/s00262-008-0598-y 18925393
18. CN Baxevanis SA Perez M Papamichail 2009 Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy Cancer Immunol Immunother 58 317 324 10.1007/s00262-008-0576-4 18704409
19. R Ramakrishnan D Assudani S Nagaraj T Hunter HI Cho S Antonia S Altiok E Celis DI Gabrilovich 2010 Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice J Clin Invest 120 1111 1124 1:CAS:528:DC%2BC3cXksVChsLo%3D 10.1172/JCI40269 20234093
20. SA Perez LG Mahaira FJ Demirtzoglou PA Sotiropoulou P Ioannidis EG Iliopoulou AD Gritzapis NN Sotiriadou CN Baxevanis M Papamichail 2005 A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival Blood 106 158 166 1:CAS:528: DC%2BD2MXlvVWjsLY%3D 10.1182/blood-2004-08-3232 15755904 (Pubitemid 40967188)
21. N Sato HJ Patel TA Waldmann Y Tagaya 2007 The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells Proc Natl Acad Sci USA 104 588 593 1:CAS:528: DC%2BD2sXovFansw%3D%3D 10.1073/pnas.0610115104 17202253 (Pubitemid 46123069)
22. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66 10.3322/canjclin.57.1.43 17237035
23. G Crivellari S Monfardini S Stragliotto D Marino SM Aversa 2007 Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses Oncologist 12 79 89 1:CAS:528:DC%2BD2sXhvValu7k%3D 10.1634/theoncologist.12-1-79 17227903 (Pubitemid 46143505)
24. B Becknell MA Caligiuri 2005 Interleukin-2, interleukin-15, and their roles in human natural killer cells Adv Immunol 86 209 239 1:CAS:528: DC%2BD2MXksFGnurk%3D 10.1016/S0065-2776(04)86006-1 15705423 (Pubitemid 40215694)
25. EM Reiche SO Nunes HK Morimoto 2004 Stress, depression, the immune system, and cancer Lancet Oncol 5 617 625 1:CAS:528:DC%2BD2cXotF2isrY%3D 10.1016/S1470-2045(04)01597-9 15465465 (Pubitemid 39303129)
26. U Nannmark ME Hokland R Agger M Christiansen J Kjaergaard RH Goldfarb U Bagge M Unger BR Johansson PA Albertsson PH Basse 2000 Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells In Vivo 14 651 658 1:STN:280:DC%2BD3M7hsFWrtA%3D%3D 11125549
27. JH Schiller D Harrington CP Belani C Langer A Sandler J Krook J Zhu DH Johnson 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92 98 1:CAS:528: DC%2BD38Xkt1OlsQ%3D%3D 10.1056/NEJMoa011954 11784875 (Pubitemid 34438899)
28. JP Sculier D Moro-Sibilot 2009 First- and second-line therapy for advanced nonsmall cell lung cancer Eur Respir J 33 915 930 1:CAS:528: DC%2BD1MXksl2ru7k%3D 10.1183/09031936.00132008 19336594
29. CE Andoniou JD Coudert MA Degli-Esposti 2008 Killers and beyond: NK-cell-mediated control of immune responses Eur J Immunol 38 2938 2942 1:CAS:528:DC%2BD1cXhsV2ntrvM 10.1002/eji.200838882 18979519
30. MA Cooper TA Fehniger A Fuchs M Colonna MA Caligiuri 2004 NK cell and DC interactions Trends Immunol 25 47 52 1:CAS:528:DC%2BD3sXhtVSjtL%2FI 10.1016/j.it.2003.10.012 14698284 (Pubitemid 38032807)
31. L Moretta G Ferlazzo C Bottino M Vitale D Pende MC Mingari A Moretta 2006 Effector and regulatory events during natural killer-dendritic cell interactions Immunol Rev 214 219 228 1:CAS:528:DC%2BD28XhtlClsrzP 10.1111/j.1600-065X.2006.00450.x 17100887 (Pubitemid 44707913)
32. F Ghiringhelli L Apetoh F Housseau G Kroemer L Zitvogel 2007 Links between innate and cognate tumor immunity Curr Opin Immunol 19 224 231 1:CAS:528:DC%2BD2sXislehsrw%3D 10.1016/j.coi.2007.02.003 17303400 (Pubitemid 46371379)
33. P Krebs MJ Barnes K Lampe K Whitley KS Bahjat B Beutler E Janssen K Hoebe 2009 NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses Blood 113 6593 6602 1:CAS:528: DC%2BD1MXotlWru7o%3D 10.1182/blood-2009-01-201467 19406986
34. J Hanna T Gonen-Gross J Fitchett T Rowe M Daniels TI Arnon R Gazit A Joseph KW Schjetne A Steinle A Porgador D Mevorach D Goldman-Wohl S Yagel MJ LaBarre JH Buckner O Mandelboim 2004 Novel APC-like properties of human NK cells directly regulate T cell activation J Clin Invest 114 1612 1623 1:CAS:528:DC%2BD2cXhtVKhur3P 15578093
35. LD Barber JA Madrigal 2006 Exploiting beneficial alloreactive T cells Vox Sang 91 20 27 1:CAS:528:DC%2BD28XnsFKkt74%3D 10.1111/j.1423-0410.2006.00775.x 16756597 (Pubitemid 43822300)
36. R Ramakrishnan S Antonia DI Gabrilovich 2008 Combined modality immunotherapy and chemotherapy: a new perspective Cancer Immunol Immunother 57 1523 1529 1:CAS:528:DC%2BD1cXovFyisbc%3D 10.1007/s00262-008-0531-4 18488219
37. J Schlom PM Arlen JL Gulley 2007 Cancer vaccines: moving beyond current paradigms Clin Cancer Res 13 3776 3782 1:CAS:528:DC%2BD2sXntFymsbw%3D 10.1158/1078-0432.CCR-07-0588 17606707 (Pubitemid 47037581)
38. PA Kosmidis HP Kalofonos C Christodoulou K Syrigos T Makatsoris D Skarlos C Bakogiannis C Nicolaides D Bafaloukos A Bamias E Samantas N Xiros I Boukovinas G Fountzilas MA Dimopoulos 2008 Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group Ann Oncol 19 115 122 1:STN:280:DC%2BD1c%2FgtVCrtw%3D%3D 10.1093/annonc/mdm430 17938425
39. GV Scagliotti F De Marinis M Rinaldi L Crino C Gridelli S Ricci E Matano C Boni M Marangolo G Failla G Altavilla V Adamo A Ceribelli M Clerici F Di Costanzo L Frontini M Tonato 2002 Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 4285 4291 1:CAS:528:DC%2BD38Xpt1CjtLs%3D 10.1200/JCO.2002.02.068 12409326 (Pubitemid 35266288)
40. G D'Addario M Pintilie NB Leighl R Feld T Cerny FA Shepherd 2005 Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature J Clin Oncol 23 2926 2936 10.1200/JCO.2005.03.045 15728229 (Pubitemid 46224111)